```html

Yellowing of the Skin or Eyes (Jaundice)

What is Yellowing of the skin or eyes (jaundice)?

Jaundice is a visible yellow discoloration of the skin, sclerae (the white part of the eyes), and sometimes the mucous membranes. It occurs when the level of bilirubin—a yellow‑orange pigment formed by the breakdown of red blood cells—rises in the blood (hyperbilirubinemia) and deposits in tissues. In healthy individuals, bilirubin is processed by the liver, turned into a water‑soluble form, and excreted in bile. When this pathway is disrupted, bilirubin accumulates and the characteristic yellow hue appears.

Jaundice is not a disease itself; it is a sign that something is interfering with the normal production, transport, metabolism, or elimination of bilirubin. Identifying the underlying cause is essential because the seriousness ranges from benign newborn physiologic jaundice to life‑threatening liver failure.

Common Causes

Below are the most frequent conditions that lead to jaundice in children and adults. Some are acute, some chronic, and several can coexist.

• Hemolytic anemia – accelerated breakdown of red blood cells (e.g., sickle‑cell disease, autoimmune hemolysis, G6PD deficiency).
• Viral hepatitis – inflammation of the liver caused by hepatitis A, B, C, D, or E viruses.
• Alcoholic liver disease & non‑alcoholic fatty liver disease (NAFLD) – chronic damage to liver cells impairs bilirubin processing.
• Biliary obstruction – gallstones, pancreatic cancer, cholangiocarcinoma, or strictures block bile flow.
• Genetic disorders – such as Gilbert’s syndrome, Crigler‑Najjar syndrome, and Dubin‑Johnson syndrome.
• Medication‑induced liver injury – acetaminophen overdose, isoniazid, certain antibiotics, and herbal supplements.
• Sepsis or severe infection – particularly in newborns (e.g., gram‑negative sepsis) or in adults with cholangitis.
• Pancreatitis – inflammation can compress the common bile duct, causing bilirubin buildup.
• Autoimmune liver diseases – primary biliary cholangitis (PBC) and autoimmune hepatitis.
• Newborn physiologic jaundice – immature liver enzymes lead to transient hyperbilirubinemia in the first week of life.

Associated Symptoms

Jaundice often appears with other clues that help pinpoint the cause. Common accompanying signs include:

• Dark urine (bilirubin excreted in urine)
• Pale, clay‑colored stools (absence of bile pigments)
• Pruritus (itching) – especially in cholestatic (bile‑flow) disorders
• Abdominal pain or fullness, especially in the right upper quadrant
• Fatigue, weakness, or general malaise
• Fever or chills (suggesting infection)
• Weight loss or loss of appetite
• Bruising or easy bleeding (indicates impaired clotting function)
• Swelling of the abdomen (ascites) or legs (edema)
• Neurologic changes—confusion, lethargy, or trembling (possible bilirubin‑induced neurotoxicity or hepatic encephalopathy)

When to See a Doctor

Jaundice should prompt medical evaluation, but urgent care is required in certain situations:

• Yellowing appears suddenly or spreads rapidly.
• Accompanying severe abdominal pain, especially in the upper right quadrant.
• Dark urine and pale stools together.
• Fever, chills, or signs of infection.
• Confusion, drowsiness, or marked change in mental status.
• Recent use of new medications, herbal products, or a known overdose.
• In infants: yellowing within the first 24 hours of life, jaundice persisting beyond 2 weeks, or rapid deepening of color.
• History of liver disease, hemolytic disorders, or cancer.

Even if symptoms seem mild, an evaluation is essential because many underlying conditions can worsen without treatment.

Diagnosis

Doctors use a step‑wise approach to determine why bilirubin is elevated.

1. Clinical assessment

• Detailed history (onset, medication, alcohol use, travel, family history).
• Physical exam focusing on liver size, tenderness, gallbladder, ascites, and neurological status.

2. Laboratory tests

• Total bilirubin and direct (conjugated) bilirubin – distinguishes hemolytic (unconjugated) from obstructive (conjugated) jaundice.
• Complete blood count (CBC) – checks for anemia or infection.
• Liver function panel: ALT, AST, alkaline phosphatase (ALP), gamma‑GT, albumin, and prothrombin time/INR.
• Hemolysis markers: haptoglobin, lactate dehydrogenase (LDH), reticulocyte count.
• Viral serologies for hepatitis A‑E, HIV, and EBV if indicated.
• Autoimmune markers (ANA, SMA, anti‑LKM) for autoimmune hepatitis.

3. Imaging studies

• Ultrasound – first‑line to evaluate gallstones, bile duct dilation, liver texture, and masses.
• CT or MRI – used when ultrasound is inconclusive or to stage tumors.
• MRCP (magnetic resonance cholangiopancreatography) – non‑invasive visualization of the biliary tree.

4. Specialized tests

• Endoscopic retrograde cholangiopancreatography (ERCP) – diagnostic and therapeutic for ductal obstruction.
• Liver biopsy – definitive for many chronic liver diseases (e.g., NASH, PBC).
• Genetic testing – for rare inherited disorders like Gilbert’s or Crigler‑Najjar.

Treatment Options

Therapy targets the root cause and may include supportive measures.

1. General supportive care

• Hydration and balanced nutrition; avoid fasting.
• Phototherapy for newborns with high indirect bilirubin (blue‑light converts bilirubin to water‑soluble forms).
• Pruritus control – antihistamines, cholestyramine, or rifampin for cholestatic itching.

2. Cause‑specific treatments

• Hemolysis: Treat underlying trigger (e.g., stop offending drug, manage autoimmune hemolysis with steroids or immunosuppressants, exchange transfusion in severe sickle‑cell crisis).
• Viral hepatitis: Antiviral therapy for hepatitis B (entecavir, tenofovir) or C (sofosbuvir‑based regimens). Supportive care for hepatitis A/E.
• Biliary obstruction: Endoscopic stone removal, stenting, or surgical bypass. Antibiotics for cholangitis.
• Alcoholic or NAFLD‑related liver disease: Alcohol cessation, weight loss, control of diabetes/hyperlipidemia; certain medications (e.g., pioglitazone) in selected cases.
• Autoimmune liver disease: Corticosteroids, azathioprine, or ursodeoxycholic acid (for PBC).
• Medication‑induced injury: Discontinue offending agent; N‑acetylcysteine for acetaminophen toxicity.
• Genetic syndromes: Gilbert’s – usually benign; Crigler‑Najjar type I may need liver transplantation; type II often responds to phenobarbital.

3. Advanced therapies

• Liver transplantation for end‑stage liver disease, acute liver failure, or certain metabolic disorders.
• Transjugular intrahepatic portosystemic shunt (TIPS) for refractory portal hypertension causing cholestasis.

Prevention Tips

While not all causes are preventable, many can be reduced through lifestyle and preventive health measures.

• Limit alcohol intake – no more than 1 drink per day for women, 2 for men.
• Maintain a healthy weight and regular exercise to lower NAFLD risk.
• Vaccinate against hepatitis A and B.
• Practice safe sex and avoid sharing needles to reduce hepatitis C transmission.
• Use medications as prescribed; discuss herbal supplements with a clinician.
• Promptly treat infections, especially urinary or biliary infections, to prevent spread to the liver.
• For newborns, ensure early feeding and follow pediatric bilirubin‑screening guidelines.
• Carry a medical alert card if you have known genetic bilirubin disorders.

Emergency Warning Signs

Key Take‑aways

Jaundice signals that bilirubin metabolism is disrupted. Because the underlying reasons vary widely—from benign genetic quirks to aggressive liver cancer—prompt evaluation is crucial. Understanding associated symptoms, knowing when to seek care, and adopting preventive habits can reduce the risk of serious complications.

References:

• Mayo Clinic. “Jaundice.” https://www.mayoclinic.org
• Cleveland Clinic. “Bilirubin and Jaundice.” https://my.clevelandclinic.org
• National Institutes of Health – LiverTox: “Drug-Induced Liver Injury.” https://www.ncbi.nlm.nih.gov
• World Health Organization. “Hepatitis Fact Sheet.” https://www.who.int
• American College of Gastroenterology. “Guidelines for the Management of Gallstone Disease.” 2023.

```